Various anti-VEGF agents, including aflibercept [263,264], bevacizumab, ranibizumab [265, 266, 267], and more recently, brolucizumab [268,269], have been used for the treatment of wet AMD. This evidence concerns the gene VEGFA and wet macular degeneration.